Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lam Trieu

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 15, 2026
Strategic engineering B cell immunity for cancer immunotherapyChengyi Li, Hrishi Venkatesh, Lam Trieu, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2025
Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancerGabriel F Alencar, Asmaa O Mohamed, Madison G Burnett, et al.
Journal for Immunotherapy of Cancer|February 4, 2026
Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeuticsThomas M Schmitt, Kelsey Furiya, Cheryl Black, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 15, 2026
Strategic engineering B cell immunity for cancer immunotherapyChengyi Li, Hrishi Venkatesh, Lam Trieu, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2025
Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancerGabriel F Alencar, Asmaa O Mohamed, Madison G Burnett, et al.
Journal for Immunotherapy of Cancer|February 4, 2026
Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeuticsThomas M Schmitt, Kelsey Furiya, Cheryl Black, et al.
Pageof 1